Jazz Pharmaceuticals PLC Files Amendment No. 1 to 2025 Annual Report on Form 10-K

Key Highlights and Shareholder Information

Jazz Pharmaceuticals PLC has filed Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The amendment, submitted to the SEC on February 24, 2026, mainly serves to update Part III of the original annual report with information that was intended to be incorporated by reference from the proxy statement for the 2026 Annual General Meeting of Shareholders. It also updates certain cover page information and the list of exhibits included in Item 15 and the Exhibit Index.

What Investors Need to Know

• Amendment Purpose: The main purpose of this filing is administrative: to provide information on directors, executive officers, corporate governance, executive compensation, security ownership, certain relationships, related transactions, director independence, and exhibits/financial statement schedules that were not included in the original annual report.
• No Material Changes or Updates: The amendment does not update or modify the other disclosures presented in the original 2025 Annual Report on Form 10-K, nor does it reflect events that occurred after the filing of that report. Investors should read this amendment in conjunction with the original report and other filings.
• Certification Updates: As required by Rule 12b-15, new certifications by the principal executive officer and principal financial officer are included as exhibits.

Shareholder and Price-Sensitive Information

• Shares Outstanding: As of April 15, 2026, Jazz Pharmaceuticals PLC had 62,735,235 ordinary shares outstanding, nominal value \$0.0001 per share.
• SEC Compliance: Jazz confirms compliance with SEC reporting requirements, including timely filings under Section 13 or 15(d) and submission of Interactive Data Files under Regulation S-T.
• Corporate Governance: Jazz Pharmaceuticals is classified as a Large Accelerated Filer, is not a shell company, and has attested to the effectiveness of its internal control over financial reporting under Section 404(b), as verified by its independent auditor.
• Insider Trading Policy: Jazz maintains strict insider trading policies and procedures, filed as Exhibit 19.1, governing directors, officers, employees, and other covered persons. This is intended to ensure compliance with laws and Nasdaq listing standards.
• Section 16(a) Compliance: All directors, officers, and persons with over 10% ownership complied with Section 16(a) reporting requirements, except for a late filing by director Patrick Enright relating to a transfer of 5,000 shares in August 2025 due to an administrative error.

Executive Compensation and Governance Updates

• Compensation Discussion and Analysis: The amendment provides detailed information about the compensation structure for named executive officers (NEOs), including base salary, performance bonus opportunities, and long-term incentive opportunities (PSUs and RSUs).
  • Compensation Philosophy: Jazz emphasizes alignment of executive compensation with company performance, shareholder value, and retention of talent. The majority of executive compensation is “at risk” and dependent on corporate performance and share price appreciation.
  • Ownership Culture: Executive share ownership guidelines are in place to further align interests between executives and shareholders.
• Factors Affecting Compensation: Compensation decisions are based on company performance, executive expertise and contribution, market data, internal pay equity, shareholder feedback, and independent business judgment of the compensation committee.

Other Noteworthy Points

• Risk Factors and Forward-Looking Statements: The amendment reiterates that the company’s forward-looking statements are subject to risks and uncertainties, and actual results may differ materially from projections. Investors should refer to the “Risk Factors” section of the original 2025 Annual Report for more detail.
• No Correction of Errors: The amendment confirms that the financial statements included do not reflect corrections to previously issued statements, nor any restatements requiring recovery analysis of incentive-based compensation under SEC rules.

Conclusion

Investor Impact: While the amendment largely serves administrative and compliance purposes, the reaffirmation of share count, compliance status, and detailed executive compensation philosophy may be of interest to shareholders tracking governance and compensation trends. There are no material changes or corrections that would directly impact share price. However, the update of executive compensation and governance practices, along with confirmation of compliance, supports investor confidence in management and controls.

Disclaimer: This article is based on Jazz Pharmaceuticals PLC’s Amendment No. 1 to its 2025 Annual Report on Form 10-K. The information provided is for informational purposes only and does not constitute investment advice. Investors are encouraged to review the full filings and consult with their financial advisors before making any investment decisions. The article does not reflect events occurring after the amendment filing date or modify disclosures affected by subsequent events.